高风险子宫内膜癌前哨淋巴结定位安全诊断算法的识别:SENTIREC-endo研究
该前瞻性全国诊断队列研究纳入216例高风险子宫内膜癌患者,其中170例接受前哨淋巴结定位、盆腔及腹主动脉旁淋巴结清扫并纳入准确性分析。24.7%存在淋巴结转移。若定位失败时行盆腔淋巴结清扫,敏感度86%、阴性预测值96%;联合切除任何PET阳性淋巴结后敏感度升至93%、阴性预测值98%。结论认为严格遵循包含切除任何PET阳性淋巴结及定位失败时行盆腔或盆腔加腹主动脉旁淋巴结清扫的算法,前哨淋巴结定位是安全的分期手术。
要点
- 高风险子宫内膜癌患者中,前哨淋巴结定位联合特定算法可安全用于分期。
- 定位失败时行盆腔淋巴结清扫,敏感度86%、阴性预测值96%。
- 联合切除任何PET阳性淋巴结后,敏感度93%、阴性预测值98%。
核心结论
- 严格遵循包含切除任何PET阳性淋巴结及定位失败时行盆腔或盆腔加腹主动脉旁淋巴结清扫的算法,前哨淋巴结定位是高风险子宫内膜癌患者的安全分期手术。
研究设计与样本
- 前瞻性全国诊断队列研究,纳入2017年3月至2023年1月的高风险子宫内膜癌女性,共216例纳入,170例接受前哨淋巴结定位、盆腔淋巴结清扫和腹主动脉旁淋巴结清扫并纳入准确性分析。
主要发现
- 170例中42例(24.7%)存在淋巴结转移。
- 算法为前哨淋巴结定位及定位失败时行盆腔淋巴结清扫,敏感度86%(95% CI 74-100),阴性预测值96%(95% CI 91-100)。
- 若盆腔淋巴结清扫联合切除任何PET阳性淋巴结,敏感度升至93%(95% CI 83-100),阴性预测值升至98%(95% CI 94-100)。
- 若定位失败时行盆腔和腹主动脉旁淋巴结清扫,获得等效结果:敏感度93%(95% CI 83-100),阴性预测值98%(95% CI 95-100)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It is unclear if sentinel node (SLN) mapping can replace pelvic- (PLD) and paraaortic lymphadenectomy (PALD) for high-risk endometrial cancer (EC). A diagnostically safe surgical algorithm, taking failed mapping cases into account, is not defined. We aimed to investigate the diagnostic accuracy of SLN mapping algorithms in women with exclusively high-risk EC. METHODS: We undertook a prospective national diagnostic cohort study of SLN mapping in women with high-risk EC from March 2017 to January 2023. The power calculation was based on the negative predictive value (NPV). Women underwent SLN mapping, PLD and PALD besides removal of suspicious and any FDG/PET-positive lymph nodes. Accuracy analyses were performed for five algorithms. RESULTS: 170/216 included women underwent SLN mapping, PLD and PALD and were included in accuracy analyses. 42/170 (24.7%) had nodal metastasis. The algorithm SLN and PLD in case of failed mapping, demonstrated a sensitivity of 86% (95% CI 74-100) and an NPV of 96% (95% CI 91-100). The sensitivity increased to 93% (95% CI 83-100) and the NPV to 98% (95% CI 94-100) if PLD was combined with removal of any PET-positive lymph nodes. Equivalent results were obtained if PLD and PALD were performed in non-mapping cases; sensitivity 93% (95% CI 83-100) and NPV 98% (95% CI 95-100). CONCLUSION: SLN-mapping is a safe staging procedure in women with high-risk EC if strictly adhering to a surgical algorithm including removal of any PET-positive lymph nodes independent of location and PLD or PLD and PALD in case of failed mapping.
引用
- Bjørnholt SM, Mogensen O, Bouchelouche K, et al. Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study. Gynecol Oncol. 2024. PMID: 38335900. doi:10.1016/j.ygyno.2024.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。